SpaceX Kicks Off Monumental AI Fundraising Drive, Signaling Industry Shift
SpaceX's new AI fundraising campaign underscores soaring demand for artificial intelligence, driving optimism across tech stocks and related hardware suppliers.
SpaceX's new AI fundraising campaign underscores soaring demand for artificial intelligence, driving optimism across tech stocks and related hardware suppliers.
Kardigan's upsized $400 million IPO for heart disease therapies highlights growing investor confidence in biotech innovation and sets a favorable precedent for…
ERock's $600 million IPO marks a major listing in the modular power sector, with proceeds targeting global expansion and next-generation energy solutions.
CoreWeave, the AI-focused cloud computing startup that has raised billions in debt and equity over the past year, is now targeting European…
SpaceX hikes Japan IPO funding target to $2.5B, marking one of the largest public offerings in Japan as Elon Musk’s space company…
Honeywell-backed Quantinuum’s $1.68 billion upsized IPO highlights surging investor interest in quantum computing and unlocks value for Honeywell’s stake.
Bitmine, the largest Ethereum treasury, announces a $300 million preferred stock offering with a 9.5% dividend, following MicroStrategy's model and potentially boosting…
Blue Owl's $300M bond sale for its tech private credit fund underscores the growing institutional demand for direct lending assets and could…
Eurazeo's successful €3.9 billion direct lending fundraise highlights the accelerating shift from traditional bank financing to private credit, positioning the firm for…
Former Meta CTO raises clean tech fund, signaling AI-driven investment opportunities in climate technology and sustainability sectors.
Bridgepoint's €5 billion European direct lending fundraise signals accelerating growth in private credit and may lift shares of the alternative asset manager.
Kardigan IPO filing marks a milestone in cardiovascular drug development, highlighting renewed investor interest in biotech innovations beyond oncology.